Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events

With the recent approval of the combinations of axitinib with the immune checkpoint inhibitor (ICI) pembrolizumab or avelumab for first-line treatment of advanced renal cell carcinoma, guidance on how to distinguish between immune-related adverse events (AEs) caused by ICI versus axitinib-related AE...

Descripción completa

Detalles Bibliográficos
Autores principales: Grünwald, Viktor, Voss, Martin H., Rini, Brian I., Powles, Thomas, Albiges, Laurence, Giles, Rachel H., Jonasch, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Consensus Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492460/
https://www.ncbi.nlm.nih.gov/pubmed/32587360
http://dx.doi.org/10.1038/s41416-020-0949-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492460/
https://www.ncbi.nlm.nih.gov/pubmed/32587360
http://dx.doi.org/10.1038/s41416-020-0949-9

Ejemplares similares